TVGN Overview

Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The Company is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.

Wall Street analysts forecast TVGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVGN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Tevogen Bio Holdings Inc revenue for the last quarter amounts to -5.40M USD, decreased -47.85

Tevogen Bio Holdings Inc. EPS for the last quarter amounts to USD, decreased

Tevogen Bio Holdings Inc (TVGN) has 18 emplpoyees as of June 29 2026.

Today TVGN has the market capitalization of 39.95M USD.